|
Polarean Imaging PLC - London-based medicalimaging technology - For 2021, annual loss widens to $14.0 million from $6.5 million in 2020. Revenue edges upwards to $1.2 million from $1.1 million. Selling & distribution expenses surge to $5.6 million from $917,783 in 2020.
Sees itself in a ‘solid financial position’ to fund itself ‘well into 2023.’ Repeats US Food & Drug Administration has accepted its new drug application resubmission. The FDA set a user fee goal date at late September, it adds. ‘We continue to identify exciting opportunities in the areas of long Covid, cardiology and pulmonary vascular disease,’ firm says.
Current stock price: 50.58 pence, up 0.2% on Wednesday
12-month change: down 48%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
